Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$1.12 USD
+0.02 (1.82%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.12 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Allogene Therapeutics, Inc. has a market cap of $240.60M, which represents its share price of $1.10 multiplied by its outstanding shares number of 218.73M. As a small-cap company, ALLO's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ALLO 1.12 +0.02(1.82%)
Will ALLO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALLO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLO
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
ALLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
Other News for ALLO
ALLO: JMP Securities Reiterates Market Perform Rating | ALLO Stock News
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
Allogene Therapeutics (ALLO) Downgraded by JP Morgan to Neutral | ALLO Stock News
Allogene Therapeutics (ALLO) Faces Price Target Cut Amid Study Setback
Allogene Resets Clinical Course After Patient Death In Lymphoma Study